FDA Approves First Generic Enoxaparin Sodium Injection to Prevent Deep Vain Thrombosis

Jul 23rd of 2010

Drugs Cardiovascular Blood & Lymphatic

The U.S. Food and Drug Administration today approved the first generic version of Lovenox (enoxaparin sodium injection), an anti-coagulant drug used to prevent deep vein thrombosis (DVT), a potentially deadly blood clotting condition.

FDA Approves New Indication for Tasigna (nilotinib)

Jun 18th of 2010

Drugs Blood & Lymphatic Leukemia FEATURED

The U.S. Food and Drug Administration today approved a new indication for Tasigna (nilotinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality.

FDA Approves Rituxan (Rituximab) to Treat Chronic Lymphocytic Leukemia

Feb 18th of 2010

Drugs Cancer Blood & Lymphatic

The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer. Rituxan, an anti-cancer drug, is intended for patients with CLL who are beginning chemotherapy for the first time and for those who have not responded to other cancer drugs for CLL. Rituxan is administered with two other chemotherapy drugs, fludarabine and cyclophosphamide.

Lenalidomide (Revlimid) Extends Disease-Free Survival in Multiple Myeloma

Jan 4th of 2010

Diseases Cancer Blood & Lymphatic FEATURED BREAKING

Initial results from a large, randomized clinical trial for patients with multiple myeloma, a cancer of the blood and bone marrow, showed that patients who received the oral drug lenalidomide (Revlimid, also known as CC-5013) following a blood stem cell transplant had their cancer kept in check longer than patients who received a placebo. The clinical trial, for patients ages 18 to 70, was sponsored by the National Cancer Institute (NCI), and conducted by a network of researchers led by the C...

Risk of Pancreatic Cancer Linked to Variation in Gene that Determines Blood Type

Sep 16th of 2009

Research Cancer Blood & Lymphatic

Common variants of the gene that determines human blood type are associated with an increased risk of pancreatic cancer, according to a study by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health, and colleagues from many universities and research institutions. The study, published online Aug. 2, 2009, in Nature Genetics, is consistent with an observation first made more than 50 years ago.

ADVERTISEMENT      |      ADVERTISE WITH US

The NHLBI Halts Study of Concentrated Saline for Patients with Shock Due to Lack of Survival Benefit

Mar 26th of 2009

Research Blood & Lymphatic

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial studying the benefits and safety of administering a highly concentrated form of saline solution in the ambulance (before hospital arrival) to trauma patients suffering from shock due to severe bleeding. The trial was stopped because patients who received the concentrated saline solutions were no more likely to survive than those who received a normal saline solution. A paral...

Researchers Decipher Blood Stem Cell Attachment, Communication

Mar 25th of 2009

Research Blood & Lymphatic

Researchers at the National Institutes of Health have deciphered a key sequence of events governing whether the stem cells that produce red and white blood cells remain anchored to the bone marrow, or migrate into the circulatory system.

FDA Approves Orphan Drug ATryn to Treat Rare Clotting Disorder

Mar 18th of 2009

Drugs Blood & Lymphatic

The U.S. Food and Drug Administration today issued its first approval for a biological product produced by genetically engineered (GE) animals.

FDA Approves RiaSTAP for Treatment of Bleeding in Patients with Rare Genetic Defect

Mar 18th of 2009

Drugs Blood & Lymphatic

The U.S. Food and Drug Administration today licensed RiaSTAP, an orphan drug for the treatment of bleeding in patients with a rare genetic defect known as congenital fibrinogen deficiency. Without treatment, these patients are at risk of potentially life-threatening bleeding.

FDA Approves Sealant to Control Bleeding During Surgery

Jan 16th of 2008

Drugs Blood & Lymphatic

On Jan. 2, the U.S. Food and Drug Administration (FDA) expanded the indication for a liquid fibrin sealant to help control bleeding during general surgery. Fibrin is a protein that helps blood clot.